



Press Release – Basel, Switzerland December 14<sup>th</sup> 2005

## TransTech Pharma Selects Genedata to Enhance High Throughput Screening Analysis

**Basel, Switzerland** – Genedata announces that TransTech Pharma has signed a multi-year license for high throughput screening analysis software Genedata Screener®. Scientists at TransTech Pharma will use Screener to enhance their efforts to develop small molecules as therapeutics for treating human diseases.

“We sought a solution that could be deployed seamlessly with our drug discovery workflow”, explained Dr. Robert Rothlein, Senior VP Biology at TransTech Pharma, Inc. Screener has been integrated with TransTech Pharma’s IT and screening infrastructure. It will automate data quality evaluation and standardize the analysis of compound bioactivity. “Genedata’s solution saves time and cost in the lead discovery workflow”.

“Screener’s modular design and open architecture were important factors in the success of our deployment at TransTech Pharma”, says Dr. Michael Lindemann, Business Head Genedata Screener. TransTech Pharma have developed a highly parallel and integrated Translational Technology® that links together drug design, synthesis and screening. “We are able to support and enhance this workflow without resource-intensive customization of the Screener platform”.

### About Genedata

Genedata specializes in computational solutions for life science research, drug discovery, and drug development. The Company combines a comprehensive, scientifically validated computational platform with expert scientific consulting services to provide tailor-made solutions for specific applications and multiple therapeutic areas. Founded in 1997 as a spin-off from Novartis, the Company is privately held and has grown to an interdisciplinary, international team of dedicated experts. Genedata is headquartered in Basel (Switzerland) with subsidiaries and branch offices in Munich (Germany), San Francisco (USA), and Boston (USA). The Company is also represented by Infocom Corporation (Japan), DigiGenomics (Taiwan), and Research Instruments (Singapore, Malaysia). For more information about Genedata, please visit [www.genedata.com](http://www.genedata.com).

### About TransTech Pharma

TransTech Pharma is a privately held clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of human therapeutics to fill unmet medical needs. The Company’s high-throughput drug discovery platform, Translational Technology®, translates the functional modulation of human proteins into safe and effective medicines. TransTech has a pipeline of small molecule clinical and pre-clinical drug candidates for the treatment of a wide range of human diseases including cardiovascular disorders, central nervous system disorders, type I/II diabetes, obesity, and oncology. In addition to its internal drug discovery programs, Trans Tech is also involved in four research collaborations with Novo Nordisk A/S, Cephalon, Inc., Merck & Co. Inc. and SIGA Technologies, Inc. For further company information, visit [www.ttpharma.com](http://www.ttpharma.com).

---

### Contact

Genedata AG  
Dr. Tobe Freeman  
Marketing Communications  
Phone +41 61 697 8510  
Fax +41 61 697 7244  
[tobe.freeman@genedata.com](mailto:tobe.freeman@genedata.com)  
[www.genedata.com](http://www.genedata.com)

TransTech Pharma, Inc.  
Stephen L. Holcombe  
Senior VP, Chief Financial Officer  
Phone +1 336 841 0300 x150  
Fax +1 336 841 0333  
[sholcombe@tppharma.com](mailto:sholcombe@tppharma.com)  
[www.ttpharma.com](http://www.ttpharma.com)

Continues...

---

**Disclaimer**

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.